Cargando…
THU353 Late Onset Of Immune Checkpoint Inhibitor-Related Diabetes After 3 Years
Disclosure: S. Avula: None. A. Ahmed: None. M. Salim: None. Z.J. Anderson: None. A. Kumar: None. A. Estrada: None. Background: Immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) is characterized by acute onset of dramatic hyperglycaemia with severe insulin deficiency following exposure t...
Autores principales: | Avula, Sreekant, Ahmed, Ammar, Salim, Michael, Anderson, Zachary J, Kumar, Ameya, Estrada, Allison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554210/ http://dx.doi.org/10.1210/jendso/bvad114.786 |
Ejemplares similares
-
THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023) -
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023) -
THU295 The Role Of Imatinib In Pediatric Diabetes
por: Lavelle, Kristen, et al.
Publicado: (2023) -
THU299 Safety Of Immune Checkpoint Inhibitor Cancer Therapy In Patients With Pre-existing Type 1 Diabetes Mellitus: A Multi-Center Cohort Study
por: Hilder, Robin, et al.
Publicado: (2023) -
THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)